Alexion’s global R&D organization is working to advance the most robust pipeline in the Company’s history. Our pipeline programs are highly focused and span several therapeutic areas including hematology, nephrology, transplant, neurology, metabolic disorders and inflammatory disorders. Today, we have programs underway with multiple highly innovative therapeutic candidates, including eculizumab, that have the potential to become first-in-class therapies for patients with severe and life-threatening disorders.

  • Preclinical
  • Early Clinical Development
  • Advanced Clinical Development
  • Registration Filings
  • Market

Soliris® (eculizumab)

Approved Indications

Paroxysmal Nocturnal Hemoglobinuria (PNH)


Soliris is approved for the treatment of PNH in nearly 50 countries, including the United States, European Union and Japan. PNH is a debilitating, ultra-rare and life-threatening blood disorder characterized by complement-mediated hemolysis (destruction of red blood cells).


Atypical Hemolytic Uremic Syndrome (aHUS)


Soliris is approved for the treatment of aHUS in nearly 40 countries, including the United States, European Union and Japan. aHUS is a life-threatening and ultra-rare chronic genetic disease that can progressively damage vital organs, leading to stroke, heart attack, kidney failure, and death.


Investigational Indications — Transplant and Neurology

Antibody-mediated Rejection (AMR) — Living & Deceased Donor


Eculizumab is being investigated as a treatment for patients undergoing kidney transplant who are at elevated risk of AMR, a life-threatening condition characterized by the acute onset of kidney failure and rapid progression to destruction of the transplanted kidney.


Relapsing Neuromyelitis Optica (NMO)


Eculizumab is being investigated as a treatment for relapsing NMO, a devastating, life-threatening, ultra-rare neurological disease that can lead to severe weakness, paralysis, respiratory failure, loss of bowel and bladder function, blindness and premature death.


Refractory Myasthenia Gravis (MG)


Eculizumab is being studied in refractory MG, a debilitating and sometimes life-threatening neurological disorder in which uncontrolled complement activation leads to destruction and inflammation at the neuromuscular junction, resulting in severe muscle weakness.


Delayed Graft Function (DGF)


Eculizumab is being evaluated in DGF, a condition in which a transplanted kidney, known as a graft, does not initially function properly. As a result, patients must undergo dialysis for a period of time following the transplant surgery.


Soliris Lifecycle Management



Investigational Candidates - Metabolic Disorders

Asfotase Alfa

Hypophosphatasia (HPP)


Asfotase alfa is a highly innovative, late-stage biologic being developed for patients with hypophosphatasia (HPP). HPP is a chronic, progressive, potentially life-threatening, genetic, and ultra-rare metabolic disease characterized by defective bone mineralization that can lead to destruction and deformity of bones, profound muscle weakness, seizures, respiratory failure and premature death.


cPMP Replacement Therapy (ALXN1101)

Molybdenum Cofactor Deficiency (MoCD) Type A


cPMP (cyclic pyranopterin monophosphate) is an enzyme co-factor replacement therapy for the treatment of patients with molybdenum cofactor deficiency (MoCD) type A, a severe, life-threatening, ultra-rare, genetic metabolic disorder that causes catastrophic and irreversible neurologic damage within the first weeks of life.


Investigational Candidates - Inflammatory Disorders

ALXN1007 Anti-Inflammatory Antibody

Antiphospholipid Syndrome (APS)


ALXN1007 is a novel anti-inflammatory antibody designed to target severe and ultra-rare inflammatory disorders.


Research Portfolio



Alexion’s Research & Development pipeline also includes several additional preclinical programs across various therapeutic areas.